PART I . 1 Table of Contents OVERVIEW Ocugen is aiming to redefine the future of vision through game-changing gene therapies with the potential to address significant, unmet medical needs. Our First-in-class, breakthrough modifier gene therapy platform presents a potential paradigm shift in treating inherited retinal diseases and blindness diseases affecting millions across the globe. Our technology pipeline includes: Novel Modifier Gene Therapy Platform OCU400 - Based on the use of nuclear horm...
Q2 FY2026 — expected 2026-09-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-04 | 2025-12-31 | 0001628280-26-014435 | EDGAR | 102K words |
| 2025-03-05 | 2024-12-31 | 0001628280-25-010271 | EDGAR | — |
| 2024-04-16 | 2023-12-31 | 0001628280-24-016378 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0001628280-23-005382 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001628280-22-004085 | EDGAR | — |
| 2021-03-19 | 2020-12-31 | 0001628280-21-005124 | EDGAR | — |
| 2020-03-27 | 2019-12-31 | 0001628280-20-004221 | EDGAR | — |
| 2019-03-22 | 2018-12-31 | 0001564590-19-008830 | EDGAR | — |
| 2018-03-15 | 2017-12-31 | 0001564590-18-005711 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001193125-17-085372 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001372299-25-000013 | EDGAR | 24K words |
| 2025-08-04 | 2025-06-30 | 0001628280-25-037310 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0001628280-25-024093 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001628280-24-047846 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001628280-24-035822 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001628280-24-023038 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001628280-23-038008 | EDGAR | — |
| 2023-08-21 | 2023-06-30 | 0001628280-23-030128 | EDGAR | — |
| 2023-05-05 | 2023-03-31 | 0001628280-23-016011 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001628280-22-028775 | EDGAR | — |
| 2022-08-05 | 2022-06-30 | 0001628280-22-021255 | EDGAR | — |
| 2022-05-06 | 2022-03-31 | 0001628280-22-012850 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-27 | 0001628280-26-021541 | EDGAR | 4K words |
| 2026-03-24 | 0001104659-26-033724 | EDGAR | — |
| 2026-03-20 | 0001104659-26-032442 | EDGAR | — |
| 2026-03-04 | 0001104659-26-023290 | EDGAR | — |
| 2026-03-04 | 0001104659-26-023288 | EDGAR | — |
| 2026-02-09 | 0001104659-26-011765 | EDGAR | — |
| 2026-01-23 | 0001104659-26-006031 | EDGAR | — |
| 2026-01-21 | 0001104659-26-005454 | EDGAR | — |
| 2026-01-15 | 0001104659-26-003900 | EDGAR | — |
| 2025-12-18 | 0001104659-25-122610 | EDGAR | — |
359 total filings indexed. 327 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001372299 |
| Ticker | OCGN |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.ocugen.com |
| Listed | 2014-12-03 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report